The association of major adverse limb events and combination stent and atherectomy in patients undergoing revascularization for lower extremity peripheral artery disease

Abstract

AbstractBackgroundThe effectiveness of combined atherectomy and stenting relative to use of each procedure alone for the treatment of lower extremity peripheral artery disease has not been evaluated.AimsThe objective of this study was to evaluate the short‐ and long‐term major adverse limb event (MALE) following the receipt of stenting, atherectomy, and the combination of stent and atherectomy.MethodsA retrospective cohort of patients undergoing atherectomy, stent, and combination stent atherectomy for lower extremity peripheral artery disease was derived from the Vascular Quality Initiative (VQI) data set. The primary outcome was MALE and was assessed in the short‐term and long‐term. Short‐term MALE was assessed immediately following the procedure to discharge and estimated using logistic regression. Long‐term MALE was assessed after discharge to end of follow‐up and estimated using the Fine‐Gray subdistribution hazard model.ResultsAmong the 46,108 included patients, 6896 (14.95%) underwent atherectomy alone, 35,774 (77.59%) received a stent, and 3438 (7.5%) underwent a combination of stenting and atherectomy. The adjusted model indicated a significantly higher odds of short‐term MALE in the atherectomy group (OR = 1.35; 95% confidence interval [CI]:1.16–1.57), and not significantly different odds (OR = 0.93; 95% CI:0.77–1.13) in the combination stent and atherectomy group when compared to stenting alone. With regard to long‐term MALE, the model indicated that the likelihood of experiencing the outcome was slightly lower (HR = 0.90; 95% CI:0.82–0.98) in the atherectomy group, and not significantly different (HR = 0.92; 95% CI:0.82–1.04) in the combination stent and atherectomy group when compared to the stent group.ConclusionsPatients in the VQI data set who received combination stenting and atherectomy did not experience significantly different rates of MALE when compared with stenting alone. It is crucial to consider and further evaluate the influence of anatomical characteristics on treatment strategies and potential differential effects of comorbidities and other demographic factors on the short and long‐term MALE risks.